By Josh White
Date: Monday 20 Oct 2025
(Sharecast News) - Avacta Group announced on Monday that it has raised £16m through an oversubscribed equity placing to accelerate development of its oncology pipeline, as new clinical data presented at the European Society for Medical Oncology (ESMO) demonstrated strong efficacy and safety for its lead program, faridoxorubicin (AVA6000).
By Josh White
Date: Wednesday 02 Jul 2025
(Sharecast News) - Avacta Therapeutics provided a second-quarter business update on Wednesday, reporting continued progress in its oncology pipeline and strengthening of its leadership team as it advanced its 'preCISION' drug development strategy.
By Josh White
Date: Friday 06 Jun 2025
(Sharecast News) - Avacta Group reported a reduced pre-tax loss of £28.98m from continuing operations in 2024 on Friday, down from £31.13m the year prior, as it accelerated its transformation into a pure-play oncology biotech.
| Currency | UK Pounds |
| Share Price | 63.80p |
| Change Today | 0.30p |
| % Change | 0.47 % |
| 52 Week High | 72.00 |
| 52 Week Low | 27.50 |
| Volume | 3,282,185 |
| Shares Issued | 411.05m |
| Market Cap | £262.25m |
| RiskGrade | 461 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| Strong Buy | 2 |
| Buy | 0 |
| Neutral | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 3 |

| No dividends found |
| Time | Volume / Share Price |
| 16:35 | 58,583 @ 63.80p |
| 16:35 | 145 @ 63.80p |
| 16:35 | 362 @ 63.80p |
| 16:35 | 109 @ 63.80p |
| 16:35 | 49 @ 63.80p |
You are here: research